Insulin lispro is an insulin analog in which the primary sequence has been altered by the inversion of amino acids B28 and B29. To date, it has not been possible to specifically measure insulin lispro in the presence of endogenous insulin because of the high degree of homology between these peptides. However, the specific determination of insulin lispro offers advantages over quantifying total concentrations of immunoreactive insulin. We therefore immunized guinea pigs and screened for antibodies with increased affinity and selectivity for insulin lispro. We prepared a monospecific antiserum by a novel immunoadsorption strategy using despentapeptide insulin. The antiserum was used to develop a competitive RIA for insulin lispro. The RIA has a low limit of quantification (17.2 pmol/L); has no interference from insulin, proinsulin, or C-peptide; and has interassay CVs of 2.6 -13.4%. The new RIA is useful for measuring serum concentrations of insulin lispro.
Human insulin lispro (Humalog ® ) is a fully potent insulin analog in which the primary sequence has been altered by the inversion of the amino acids at positions 28 and 29 of the B chain ( Fig. 1) (1-3) . This inversion causes insulin lispro to have a reduced capacity for dimerization, which promotes the dissociation of insulin hexamers directly to monomers (3, 4) . Consequently, insulin lispro has a faster rate of absorption, higher peak serum concentrations, and a shorter duration of action than regular human insulin after subcutaneous injection (2, 3, 5) . For individuals with type 1 diabetes, insulin lispro has several advantages, including improved postprandial control of blood glucose, reduced frequency of hypoglycemic episodes, and therapeutic convenience compared with Humulin ® R (6 -8) .
The small structural difference between insulin lispro and insulin has frustrated attempts to specifically measure insulin lispro in the presence of endogenous insulin. Accordingly, a conventional insulin RIA has been used to date for measuring serum concentrations of insulin lispro after subcutaneous administration (5, 9) . However, this analytical strategy permits the assessment of insulin lispro pharmacokinetics only in terms of total (insulin plus insulin lispro) "immunoreactive insulin". The specific determination of insulin lispro offers advantages over measuring total concentrations of immunoreactive insulin and would be particularly useful in assessing the pharmacokinetics of insulin lispro in patients with insulin resistance and in documenting factitious hypoglycemia from injection of insulin lispro. However, the lack of a suitable antiserum has precluded the development of an RIA specific for insulin lispro. We therefore initiated experiments to investigate the feasibility of developing an insulin lispro specific antiserum.
After immunization of guinea pigs with insulin lispro and screening of sera for antibodies with increased affinity and selectivity for insulin lispro vs native human insulin, we prepared a monospecific polyclonal antiserum by a novel immunoadsorption strategy using despentapeptide insulin (DPI), 4 an analog of human insulin lacking the five terminal amino acids at the carboxy terminus of the B chain. We used the monospecific antiserum in the successful development of a competitive RIA. albumin (BSA) and polyethylene glycol (M r 8000) were obtained from Sigma Chemical Co. Normal guinea pig serum and lactoperoxidase were purchased from Calbiochem. Goat anti-guinea pig IgG was obtained from Jackson ImmunoResearch. Na 125 I was purchased from NEN Life Science Products. Affigel-15 was obtained from Bio-Rad Laboratories. Sterile saline was purchased from Baxter Healthcare. Human serum from fasted healthy adults was obtained from Western States Plasma Company. All other reagents were of analytical grade. preparation of radiolabeled peptides.
Biosynthetic insulin and insulin lispro were radoiodinated by a conventional lactoperoxidase method (10) . We isolated the [ 125 I]-monoiodo-Tyr(A14) peptides by preparative C 18 reversed-phase HPLC using isocratic elution with 0.20 mol/L ammonium acetate-275 mL/L acetonitrile, pH 5.5. The specific activity of [ 125 I]-monoiodo-Tyr(A14) insulin and insulin lispro was routinely Ն350 Ci/g.
production of anti-insulin lispro antiserum
Immunization and antiserum generation. The insulin lispro immunogen was prepared by dissolving reference standard insulin lispro (LY275585, lot no. RS0195) in 9 g/L sodium chloride at a concentration of 2 g/L. The immunogen solution was stored as 0.5-mL aliquots in plastic vials at Ϫ20°C. Antibodies were produced in Duncan-Hartley guinea pigs at Covance (Denver, PA). For the initial immunization, the immunogen was emulsified with an equal volume of Freund's complete adjuvant. Twelve male guinea pigs were then immunized with 0.4 mg of the immunogen by multiple subcutaneous nuchal injections. For booster injections, the immunogen was emulsified with an equal volume of Freund's incomplete adjuvant. The guinea pigs received subcutaneous booster injections of 0.2 mg at 3, 6, and 9 weeks. Beginning at 12 weeks, the guinea pigs received booster injections of 0.1 mg of immunogen at 1-month intervals. Antibody titers were assessed by RIA in bleeds collected 10 days after each booster injection beginning 1 month after the initial immunization.
Antiserum immunoadsorption. Cross-reactive insulin antibodies were removed by immunoabsorption of the antisera using DPI coupled to Affigel-15. DPI-Affigel-15 affinity gel was prepared according to the manufacturer's instructions. Briefly, 16 mL of a 500 g/L slurry of gel was washed on a scintered glass funnel with cold deionized water, dried to a moist cake, and then transferred immediately to a polypropylene tube containing 8 mL of a 1 g/L solution of DPI prepared in 100 mmol/L HEPES, pH 7.5, (1 mL protein/mL gel). After sealing the tube, we incubated the mixture on an orbital rocker at 4°C for ϳ16 h. Any remaining unreacted sites were blocked by incubating the gel with 1 mL of 1 mol/L Tris, pH 7.5, for 1 h at 20°C. Before use, the gel was washed extensively with 0.1 mol/L HEPES, pH 7.5, and stored in HEPES buffer containing 0.2 g/L sodium azide.
Two pools of antisera were prepared by combining bleeds 3-7 from guinea pigs 1221 and 1222. Each lot was diluted 1:1 with assay buffer, which consisted of 100 mmol/L sodium phosphate, 20 g/L EDTA, 1 g/L sodium azide, 0.5 mL/L Tween-20, and 1 g/L BSA, adjusted to pH 7.5; the final volumes of each diluted pool was ϳ30 mL. The DPI-Affigel-15 gel was equilibrated with an equal volume of assay buffer for 1 h at 20°C before antiserum adsorption. The two antisera pools from guinea pigs 1222 and 1221 were mixed with a total of 1 and 10 mL, respectively, of a 500 g/L slurry of DPI-Affigel-15 and incubated on an orbital rocker at 4°C for 16 h. After immunoadsorption, the antisera were centrifuged, filtered through a 0.45 m filter, combined into a single lot, and stored at Ϫ70°C. We diluted the pooled antiserum 1:10 000 with assay buffer for use in the RIA. Clinical Chemistry 45, No. 1, 1999 insulin lispro ria RIA solutions. All solutions except the stock solutions of antiserum and peptide calibrators were stored at 4°C. The assay buffer used to dilute the tracer and antibody contained 100 mmol/L sodium phosphate, 20 g/L EDTA (dipotassium salt), 1 g/L sodium azide, 0.5 mL/L Tween-20, and 1 g/L BSA, and was adjusted to pH 7.5 (11) . A 1 mg/L solution of insulin lispro was prepared in assay buffer containing 30 g/L BSA and 6 g/L NaCl (sample buffer) and was stored frozen in 1-mL aliquots in polypropylene vials at Ϫ20°C. Calibration curves were prepared daily, using dilutions of this stock solution in human serum. A solution of nonimmune guinea pig serum was prepared by reconstituting one vial of serum with 5 mL of Alpha-Q water and diluting to final a concentration of 20 mL/L with assay buffer. We prepared the precipitation reagent of 20 mL/L goat anti-guinea pig IgG and 60 g/L polyethylene glycol in a buffer containing 100 mmol/L sodium phosphate, 20 g/L EDTA, 1 g/L sodium azide, and 0.5 mL/L Tween-20, pH 7.5.
RIA procedure. Each binding reaction (total volume, 400 L) was performed in 12 ϫ 75 mm polypropylene tube and consisted of 100 L of radioiodinated insulin lispro tracer (50 pg/tube), 100 L of antiinsulin lispro antiserum (diluted 1:10 000), and 200 L of human serum or polyethylene glycol-treated serum (12) . The nonspecific binding was determined by replacing the antiserum with assay buffer. After the sample was mixed, we incubated the binding reaction at room temperature for 18 -24 h. The bound and free forms of insulin lispro were separated by addition of 100 L of 20 mL/L nonimmune guinea pig serum in assay buffer, followed by 1 mL of a cold precipitation reagent. Each tube was vortex-mixed thoroughly and incubated at 4°C for 1 h. After each tube was centrifuged at 3000g for 15 min at 4°C, we decanted the aqueous phase and measured the radioactivity in the precipitate in a gamma counter. A VAX computer was used to analyze the RIA data by a weighted four-parameter logistic model algorithm (13) . The insulin lispro concentration in test samples was estimated from a serum calibration curve that ranged in concentrations from 0.01 to 100 g/L (1.7 to 17 200 pmol/L).
assay validation
The insulin lispro RIA was validated to support bioavailability, bioequivalence, and pharmacokinetic studies in animals and man (14) . Intra-and interassay imprecision (CVs), recovery, and serum stability of insulin lispro were assessed by measuring the concentrations of insulin lispro in control samples that were prepared by adding reference standard insulin lispro to serum from healthy adults at concentrations of 0.1-100 g/L. Serum controls were stored frozen in aliquots at Ϫ20°C. We compared the cross-reactivities of insulin lispro and the endogenous peptides, insulin, proinsulin, and C-peptide, as well as 40 other structurally related analogs to map the binding epitope. In assays to assess stability, we measured the concentration of insulin lispro in each of three serum samples at three time points in duplicate. Insulin lispro was considered to be stable if the recovery measured by RIA was Ϯ 20% of the nominal concentration.
assay comparison
For this comparison we measured the "free" insulin lispro concentrations in serum samples from a clinical study designed to evaluate different protamine formulations of insulin lispro. This study was conducted in accordance with the ethics principles stated in the latest version of the Declaration of Helsinki and applicable guidelines for good clinical practice. The protocol was approved by the local Institutional Review Board, and each participant gave informed consent. In this glucose clamp study, 12 individuals with type 1 diabetes were connected to a Biostator ® to maintain euglycemia. Before starting the study, each patient received a continuous intravenous infusion of human insulin in their contralateral arm for ϳ3 h to attain a stable blood glucose of 0.9 Ϯ 0.1 g/L (90 Ϯ 10 mg/dL). Upon subcutaneous injection of a single dose of 0.3 units/kg of one formulation of insulin lispro, the insulin infusion was terminated, and blood samples were collected, without anticoagulant, for up to 19 h. To remove anti-insulin antibodies from the patients' sera, the test samples were treated with an equal volume of icecold 200 g/L polyethylene glycol, followed by centrifugation (12) . The concentrations of insulin lispro were then measured in the supernatants by the new RIA and a validated conventional insulin RIA (9) .
Results

antiserum characterization
All guinea pigs produced antibodies to insulin lispro; however, the binding of insulin and insulin lispro tracers varied substantially between animals. Most antisera displayed a slight preference for insulin lispro tracer. Antisera from two guinea pigs displayed suitable affinity and selectivity for use in an insulin lispro-specific RIA, but both displayed cross-reactivity with native human insulin. We therefore used immunoadsorption to remove cross-reactive insulin antibodies. Because of the differing amounts of anti-insulin antibodies, the antiserum from guinea pig 1221 was treated three times, whereas the antiserum from animal 1222 was treated only once. Although the antibody titers were diminished by immunoadsorption, both antisera showed a marked enhancement in their selectivity for insulin lispro (Fig. 2) . The final antiserum, prepared by pooling the two treated antisera, displayed a Ͼ30-fold selectivity for insulin lispro with negligible cross-reactivity with either human insulin or proinsulin at concentrations as high as 100 g/L (Fig. 3 ).
epitope mapping (antiserum specificity)
We evaluated the cross-reactivity of 40 structurally related peptides in competitive binding RIAs to evaluate the specificity of the treated antiserum ( Table 1 ). The percentage of cross-reactivity was calculated as the ratio of the ED 50 of insulin lispro to the ED 50 (concentration of unlabeled peptide necessary to produce 50% displacement of radiolabeled insulin lispro) of each peptide. As expected, modifications to the carboxy terminus of the B chain produced the greatest disruptions in antigenicity. Modifications at other B-chain residues did not alter crossreactivity with the antiserum. A marked reduction in cross-reactivity occurred when the lysine at B28 was substituted with either an acidic or neutral aliphatic amino acid. Any modification that removed proline from the B29 position ablated cross-reactivity with the antiserum. The proinsulin analog of insulin lispro was only half as potent as insulin lispro, indicating that a free B-chain carboxy terminus is required for full immunoreactivity. These data suggest that the insulin lispro antigenic determinant comprises charge, steric, and secondary structural components. The endogenous human peptides, insulin, proinsulin, and C-peptide, all displayed negligible cross-reactivity at physiological and pharmacological concentrations ( Table 1 and Fig. 3 ).
assay performance
Calibration curve parameters. A typical calibration curve for insulin lispro prepared in human serum is shown in Fig.  3 . For 12 RIAs, the percentage of nonspecific binding was 1.9% Ϯ 0.15% (mean Ϯ SE), with a maximum binding of 40.5% Ϯ 0.45%. The slope and ED 50 were 0.99 Ϯ 0.01 and 0.94 Ϯ 0.04 g/L, respectively.
Recovery. Intra-and interassay CVs are reported in Table  2 . The intraassay CVs were 6.1-19%, and the interassay (Top), antiserum from guinea pig 1221 was treated with DPI-Affigel-15 as described in Materials and Methods. Each data point represents the mean of duplicate determinations. Data are plotted as the ratio of the bound cpm in the presence of unlabeled peptide (B) relative to the maximum binding in the absence of unlabeled peptide (B 0 ). As shown, the cross-reactivity of insulin lispro was not affected by immunoadsorption (E, before first treatment; F, after third treatment). In contrast, the cross-reactivity of human insulin was markedly reduced by immunoadsorption (‚, before first treatment; OE, after third treatment). (Bottom), antiserum from guinea pig 1222 was treated with DPI-Affigel-15 as described in Materials and Methods. Each data point represents the mean of duplicate determinations. Data are plotted as the ratio of the bound cpm in the presence of unlabeled peptide (B) relative to the maximum binding in the absence of unlabeled peptide (B 0 ). As shown, the cross-reactivity of insulin lispro was unaffected by immunoadsorption (E, before treatment; F, after treatment). In contrast, the cross-reactivity of human insulin was reduced to a negligible amount by immunoadsorption (‚, before treatment; OE, after treatment). CVs were 2.6 -13%. Recoveries (Table 3) ranged from 96% to 108% at concentrations of 0.1-25 g/L (n ϭ 4 -12).
Linearity. The linearity of dilution was established with a sample of human serum supplemented with 100 g/L of insulin lispro and diluted 1:5, 1:10, 1:50, 1:100, and 1:200 with human serum. The overall mean recovery was 93.4% Ϯ 1.8% (mean ϩ SE; n ϭ 10).
Stability. Insulin lispro was stable in serum for at least 6 months when stored frozen at Ϫ20°C, which is consistent with a previous report of stability in serum for up to 18 months at Ϫ20°C (9) . Insulin lispro was stable in human serum for at least 7 days at 4°C, 24 h at room temperature, and for at least three cycles of freezing and thawing.
assay comparison
We compared the new RIA with a conventional insulin RIA that has been used extensively to support clinical studies of insulin lispro (9, 15) . The serum concentrations determined by both assays are plotted against each other in Fig. 4 , with the new RIA as the y variable and the conventional insulin RIA as the x variable. When the data were segregated according to the concentration of immunoreactive insulin, linear regression analysis yielded two different relationships. When the concentration of free immunoreactive insulin was Յ0.8 g/L (138 pmol/L), the equation was: y ϭ 0.93x ϩ 0.03; r ϭ 0.87. The slope, 0.93, was not statistically significantly different from 1.0 (P ϭ 0.331). These data demonstrated excellent agreement between assay results for the new method and the standard insulin RIA. Therefore, when the majority of the immunoreactive insulin in the test sample was insulin lispro, there was close agreement in assay results between these two methods. However, when the concentration of free immunoreactive insulin was Ͼ0.8 g/L the equation was: y ϭ 0.52x Ϫ 0.09; r ϭ 0.94. In this case, the slope, 0.52, differed significantly from 1.0 (P Ͻ0.001). Thus, when insulin is a major fraction of the serum "insulin immunoreactivity", the insulin RIA detects both insulin and insulin lispro. This produces a lack of agreement between the RIAs, with a slope value no longer close to unity.
The conclusions from linear regression analysis were confirmed by a concordance analysis that evaluates agree- ment between paired observations (16) . The concordance coefficient (r c ) for the pairs of observed insulin lispro and insulin concentrations in samples with low baseline concentrations of immunoreactive insulin was 0.862, which confirms a high degree of agreement (for test of r c ϭ 0, P Ͻ0.001). The value of r c for the samples with concentrations of immunoreactive insulin Ͼ0.8 g/L was 0.397 (P ϭ 0.083), which confirmed the lack of agreement between the assays for this subset of the samples.
Discussion
Two sources of evidence indirectly supported the feasibility of developing insulin lispro specific antibodies. First, insulin lispro has been reported to display reduced potency in some insulin RIAs (15) . Second, epitope map-ping studies of human insulin have revealed that the carboxy terminus of the B chain contains one of two antigenic determinants on insulin (17) (18) (19) (20) , the other being the immunodominant A-chain loop, which comprises residues A8 -A10 (21) (22) (23) (24) . Other studies have demonstrated that murine anti-insulin monoclonal antibodies are capable of detecting minor structural changes in the terminal B30-Thr of human insulin (19, 20) . Marks et al. (18) reported binding data that suggest that the C-terminal antigenic determinant of insulin comprises amino acids B27-B30. We selected the guinea pig for development of an insulin lispro-specific antiserum because species specificity is recognized to play an important role in the successful generation of anti-insulin antibodies (17) . Because all antisera displayed different cross-reactivities with native human insulin (Fig. 2) , we developed a novel immunoadsorption strategy, using DPI coupled to Affigel-15. Because DPI lacks the five terminal amino acids at the carboxy terminus of the B chain, the affinity gel is capable of removing all antibodies against epitopes common to insulin and insulin lispro except for those directed against the carboxy terminus of the B chain. After immunoadsorption, the antiserum displayed a Ͼ30-fold selectivity for insulin lispro, with negligible cross-reactivity with human insulin, proinsulin, and C-peptide at concentrations up to 100 g/L ( Table 1 and Fig. 3 ).
Cross-reactivity experiments indicated that the amino acid sequence -Xaa-Pro-Thr-COOH (where Xaa is a basic amino acid) at B28 -B30 is the antigenic determinant. First, modifications to this region produced the greatest disruption in antigenicity (Table 1) , and native human insulin displays cross-reactivity. In contrast, amino acid substitutions at residues near the amino terminus of the B chain had no effect on antigenicity. Second, a basic amino acid, such as lysine, arginine, or ornithine, was required at residue B28 for full cross-reactivity. Cross-reactivity was markedly reduced when the lysine at B28 was replaced with either an acidic or a large neutral aliphatic amino acid. Third, a proline is required at B29, because any modification that removes proline ablated cross-reactivity with the antiserum. Optimal cross-reactivity was achieved when the peptide chain terminated at B30; this indicated that a free B-chain carboxy terminus is required for full antigenicity.
In summary, we describe the first assay that permits the specific determination of insulin lispro and is suitable for measuring insulin lispro in the presence of endogenous or pharmacological concentrations of both proinsulin and insulin in human and canine sera. We conclude the new RIA is a valid method that will be useful in future studies to assess the serum concentrations of insulin lispro.
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